Loading
Life sciences · Journal article
Expert Review of Molecular Diagnostics · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Pregnant women living with HIV (PWLWH) experience cardiometabolic risk across pregnancy and postpartum, including hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), dyslipidemia, obesity, and later metabolic disease. This heterogenous biology reflects gestational adaptation, HIV-associated immune adaptation, antiretroviral therapy (ART), placental function, and underlying cardiometabolic susceptibility. Integrated proteomic-metabolomic prediction studies in PWLWH remain scarce, positioning current evidence as a foundation for biomarker discovery and prospective validation. AREAS COVERED: This review evaluates molecular and biomarker evidence from PWLWH alongside broader pregnancy literature informing proteomic and metabolomic discovery. Approaches include mass-spectrometry-based proteomics and metabolomics, affinity-based platforms including Olink and SomaScan, nuclear magnetic resonance, targeted assays, and multi-omics integration using regression, network, machine learning, and latent-factor methods. Emphasis is placed on inflammatory, endothelial, angiogenic, lipid, amino-acid, mitochondrial, and immune-metabolic pathways relevant to HDP, GDM, dyslipidemia, and postpartum cardiometabolic risk. EXPERT OPINION: Integrated proteomics and metabolomics offer near-term value for mechanistic discovery and reproducible molecular risk signatures. Translation requires longitudinal cohorts, measured ART exposure, standardized pre-analytics, independent validation, and improvement beyond clinical risk factors. High burden settings additionally require resource-appropriate sampling, simplified targeted assays, local laboratory capacity, sustainable bioinformatics, demonstrable clinical utility, and scalable translational strategies.